Are the immuno-stimulatory properties of Lenalidomide extinguished by co-administration of Dexamethasone?
Dexamethasone has been a mainstay of anti-myeloma therapy for 20 years. However, it is intensely immunosuppressive and may limit the efficacy of the immune system to control myeloma, and limit the exciting opportunities to use immune stimulating drug therapies such as Lenalidomide to maximize the fight against this disease.
Haematology and Immunology Translational Research Laboratory; Peter MacCallum Cancer Centre; St Andrews Place; East Melbourne, Australia.
Andy
A
Hsu
David S
DS
Ritchie
Paul
P
Neeson